Sector News

Valeant doubles size of its HQ as deal spree continues

September 2, 2015
Life sciences

Serial buyer Valeant is expanding quickly, and to keep up, it’s expanding its office space, too.

The Canadian pharma has leased another 310,000 square feet at Somerset Corporate Center in Bridgewater, NJ, doubling its footprint at the complex less than two years after setting up its U.S. headquarters there, NJBIZ reports.

Valeant now leases two full buildings at the office park, and it’s extended the term of its original lease, too, the publication notes. The company amped up its New Jersey presence in 2013 with its buyout of Bausch & Lomb, consolidating its operations in the state from sites that included another in Bridgewater.

The move may come as no surprise to those who have been keeping track of Valeant’s latest acquisition spree. Early in the year, it inked pacts to pick up GI specialist Salix and the assets of bankrupt biotech Dendreon, later agreeing to buy Egypt’s Amoun Pharma to beef up in emerging markets. Last month, it announced a deal to nab Sprout Pharmaceuticals, the maker of a female libido drug, Addyi, that had won its FDA green light just one day prior. And Wednesday it announced a tuck-in deal with surgical business Synergetics USA.

Valeant isn’t alone in choosing New Jersey as a hub. Johnson & Johnson, Merck & Co., Novartis, Bristol-Myers Squibb, Sanofi and Bayer are all corporate citizens–and Allergan, the company that swooped in to steal the Botox-maker from Valeant after a months-long hostile pursuit, calls the Somerset center home as well.

According to Steven Pozycki, the CEO of SJP Properties, which owns the complex, New Jersey has its convenient highway system and strong labor pool to thank, in part, for its large pharma presence. The latter, in particular, will offer the company “a distinct competitive advantage in attracting in retaining top talent,” he said in a statement.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach